


Journal of applied cosmetology

1
IV MEETING ON COSMETIC DERMATOLOGY
Program



Official Journal of International Society of Cosmetic Dermatology


INTERNATIONAL
EDIMME



Volume 9 - Number 1
January/March 1991
ISSN 0392-8543 Sped. abb. post. IV°70



BETAEFFE®

**prevenzione dell'invecchiamento
coadiuvante nelle fotoprotezioni
e nelle fotodermatosi
dermatosi a sfondo distrofico**



PRODOTTO DIETETICO autorizzazione del Ministero della Sanità N. 706/4996 del 19-7-84

Per Campioni Medici e Documentazione Scientifica:
Mavi Sud s.r.l. - Viale dell'Industria, 1 - 04011 Aprilia (LT) Tel. (06) 9281235/6/7 - Fax (06) 9281523

VISO E CORPO

Una cura completa
per la pelle



mavi

La ricerca scientifica nella dermocosmesi


Mavi Sud Srl - Viale dell'Industria, 1 - 04011 Aprilia (LT)


PCL-liquid and PCL-solid
were launched 25 years ago.
Since then, they have found
their way into well over
10 billion units of cosmetics,
the world over.
Their use is still spreading.
There are no finer emollients.


PCL-liquid und PCL-solid
are non-greasy, non-occlusive,
water-resistant wax esters.
They spread readily on the skin surface.



DRAGOCO






INTERNATIONAL
EDIEMME

Via Innocenzo XI, 41 - 00165 Roma (Italy) Tel. (06) 63.78.788

DERMATOLOGIA COSMETOLOGICA

A cura di P. Morganti e L. Muscardin
Ed. International Ediemme

Indice 1° Volume

Sezione I Considerazioni Generali

- 1 Cenni storici
- 2 La bellezza della figura umana

Sezione II Fisiologia e Biologia della cute

- 3 Sviluppo della pelle
- 4 La struttura della cute
- 5 Biochimica e Fisiologia dell'epidermide
- 6 Biologia del tessuto connettivo
- 7 Sistema Vascolare ed innervazione della cute

Sezione III La Cute come organo di assorbimento

- 8 Nozioni basilari sulla permeabilità e sull'assorbimento
- 9 Membrane e assorbimento
- 10 Metabolismo della cute e degli annessi cutanei

Sezione IV Chimica e Chimico-Fisica dei preparati topici

- 11 Materie prime e principi attivi di uso cosmetologico
- 12 Emulsioni ed emulsionanti
- 13 Tensioattivi di uso cosmetico
- 14 Gli antiossidanti e i fenomeni ossidativi dei grassi
- 15 Antimicrobici e preservanti cutanei
- 16 La profumazione dei cosmetici
- 17 Chimica e tossicologia dei coloranti
- 18 Prodotti cosmetici in aerosol

Indice 2° Volume

Sezione V Trattamenti dermocosmetici del viso e del corpo

- 19 Detersione, protezione e normalizzazione della pelle
- 20 La cosmesi per l'uomo
- 21 Cosmetici per bambini
- 22 Preparati per il bagno
- 23 Maschere e peeling
- 24 I Depilanti

Sezione VI La cute senile

- 25 Invecchiamento cutaneo
- 26 Il trattamento della cute senile

Sezione VII Cosmetici e Psiche

- 27 Aspetti psicosomatici e somatopsichici in dermatologia cosmetologica

Sezione VIII I danni cutanei

- 28 Patologia cutanea da cosmetici su base immunologica
- 29 Danni da cosmetici

Sezione IX Annessi cutanei e dermocosmesi

- 30 Ghiandole sudoripare e sebacee
- 31 Deodoranti e antisudore
- 32 Struttura e proprietà dei capelli
- 33 Detersione, protezione e normalizzazione dei capelli e del cuoio capelluto
- 34 Cosmetici decorativi ad effetto duraturo
- 35 Le unghie
- 36 Prodotti decorativi ad effetto temporaneo superficiale

Indice 3° Volume

Sezione X Seborrea e dermocosmesi

- 37 Caratteristiche chimico-fisiche e funzioni fisiologiche del sebo
- 38 Produzione e modificazioni del sebo nel sano e nel seborroico
- 39 Influenza dei trattamenti cosmetologici sui lipidi di superficie del viso e del capillizio
- 40 Attività ormonale e ghiandole sebacee
- 41 Il problema terapeutico dell'acne
- 42 Possibilità terapeutiche nella seborrea

Sezione XI Melanogenesi e dermocosmesi

- 43 Il sistema pigmentario
- 44 Filtri solari, pigmentanti diretti e depigmentanti

Sezione XII Mucose orali e dermocosmesi

- 45 La salute della bocca e dei denti
- 46 Profilassi ed igiene dei denti e della bocca
- 47 Preparazioni cosmetiche per la cavità orale

Sezione XIII Prodotti speciali

- 48 Omeopatia e cosmetici
- 49 Soluzioni per lenti a contatto
- 50 Cosmetici ipoallergenici
- 51 Cosmesi su basi naturali

Sezione XIV Trattamenti estetici correttivi

- 52 Interventi correttivi di chirurgia plastica
- 53 Laserterapia
- 54 Crioterapia
- 55 Principi di mesoterapia
- 56 Ionoforesi
- 57 Interventi correttivi di "camouflage"

Sezione XV Controlli dermatossicologici

- 58 Valutazione delle materie prime e dei cosmetici finiti
- 59 Controlli tossicologici delle materie prime e del prodotto finito
- 60 Cosmetognosi. Funzionalità ed efficacia dei prodotti cosmetici

Sezione XVI Problemi normativi e di Marketing

- 61 Nozioni di marketing e di pubblicità
- 62 Grafica pubblicitaria: implicazioni psicologiche
- 63 Normative di legge sui cosmetici nei vari paesi del mondo
- 64 La responsabilità civile dei trattamenti cosmetici
- 65 Giudizio medico-legale del danno estetico

INFORMAZIONI PER L'ACQUISTO

Il pagamento di Lit. 120.000 (Centoventimila) per l'acquisto del 1° volume di **Dermatologia Cosmetologica** può essere effettuato mediante assegni di conto corrente o per contanti indirizzandoli a:

INTERNATIONAL EDIEMME Via Innocenzo XI, 41 - 00165 ROMA
c/c bancario n. 29612/2 Banco di Santo Spirito Ag. 23, 00165 ROMA

☐ Prenoto fin da ora i volumi 2° e 3°

Con la presente richiedo:

Copie n. del Volume n. 1

☐ Invio in contrassegno

☐ Accudo assegno n. (a pagamento quale anticipo di prenotazione)

Nome Indirizzo

TIMBRO E FIRMA

Specificare condizioni di pagamento e fornire N° Codice Fiscale se è richiesta fattura.

MAVIGEN BAGNO

**Il detergente naturale
dall'azione delicata,
protettiva, emolliente e lenitiva.**



La ricerca scientifica nella dermocosmesi.

**Per Campioni Medici e Documentazione Scientifica scrivere a:
Mavi Sud Srl - Direzione Propaganda Medica - Viale dell'Industria 1 - 04011 Aprilia (LT).**

MAVIGEN SHAMPOO

Shampoo al collagene
per lavaggi frequenti

LPO

Balsamo protettivo e riparatore



La ricerca scientifica nella dermocosmesi.

Per Campioni Medici e Documentazione Scientifica scrivere a:

Mavi Sud Srl - Direzione Propaganda Medica - Viale dell'Industria 1 - 04011 Aprilia (LT).


DALLA RICERCA MAVI GLI IDRATANTI A PERMEABILITA' SELETTIVA



IDRATAZIONE NORMALE
per pelle da normale a grassa



IDRATAZIONE MEDIA
per pelle da normale a secca



IDRATAZIONE FORTE
trattamento intensivo
per ogni tipo di pelle

GEL IDRATANTE a *fattore di idratazione 5*. Reidratante cutaneo leggero per la pelle da normale a grassa. Arricchito con PCA noto componente dell'NMF, glicina, collagene "attivo" e filtri UVA - UVB.

CREMA a *fattore di idratazione 10*. Idratante cutaneo per pelli da normali a secche. Arricchita con acido gamma-linolenico, PCA, collagene "attivo", speciali umettanti, glicina e filtri UVA - UVB.

GEL-EMULSIONE monodose, a *fattore di idratazione 20*, **privo di conservanti**. Idratante cutaneo per pelli particolarmente sensibili e disidratate ad alta concentrazione di principi attivi per tutti i tipi di pelle. Arricchito con acido gamma-linolenico, fosfolipidi, speciali olii ramificati e filtri UVA - UVB.



**L'IDRATAZIONE E L'ASSORBIMENTO PROGRAMMATI
CON PRECISI INDICI NUMERICI**



La ricerca scientifica nella dermocosmesi.

Mavi Sud S.r.l. - Viale dell'Industria, 1 - 04011 Aprilia (LT).



QUICK MOIST
L'alimento
per la pelle

IDROSKIN 5-10-20 Gli idratanti a permeabilità selettiva



MM
mavi

La ricerca scientifica nella dermocosmesi

Mavi Sud s.r.l. - Viale dell'Industria, 1 - 04011 Aprilia (LT)

A new look at old skin: A challenge to cosmetology

1st International Meeting on Cosmetic Dermatology,
Rome, Italy, March 7-9, 1985

Editors: P. Morganti, W. Montagna



The proceedings contained in this volume provide comprehensive view of the different aspects of the skin aging with its cosmetological implications.

Contents (main chapters)

The problems of the aged (*R. Butler*)

Nutrition and aging (*M. Proja*)

Common structural changes in aging human skin (*W. Montagna*)

An overview of physiological changes (*B.A. Gilchrest*)

The skin as a barrier and a homeostatic compartment of the body (*G. Esposito*)

Skin collagen cross links natural and unnatural (*J.P. Bentley*)

Aging changes in the mucus membranes (*A. Jarrett*)

Changes in Cutaneous appendages (*F.J.G. Ebling*)

Sebum secretion rates in relation to age: A new look (*J.S. Strauss*)

Aging skin and Sun Damage (*F. Serri, L. Celleno*)

Sunlight, age and skin cancer (*J.C. van der Leun*)

Stereology of the skin surface: a comparison between ageing and UV-induced damages (*P. Corcuff*)

Cosmetic wrinkle smoothing (*A. Meybeck*)

Collagen in cosmetic formulations: A contribution to research on aging skin (*I. Beyssac*)

The cosmetic make-over in elderly women (*A.M. Kligman*)

Essential fatty acids and skin aging (*P. Morganti, S.D. Randazzo*)

Treatment cosmetics and aging (*L.C. Calvo*)

Readership:

Third year undergraduates, research workers in the field of Cosmetic Chemistry, Biochemistry, Medicine, Pharmacy and Pharmacology, researchers and managers working in the cosmetic and pharmaceutical industries.

**A NEW LOOK AT OLD SKIN:
A CHALLENGE TO COSMETOLOGY**

Editors: P. Morganti,
W. Montagna

Proceeding of 1st International Meeting on Cosmetic Dermatology,
Rome, Italy, March 7-9, 1985, 1986;

17-24 cm. 400 pages, Hardbound In Italy L. 100.000;
ISSN 0393-5779



International Society of Cosmetic Dermatology

PRESIDENT

Coleman Jacobson (USA)

HONORARY PRESIDENT

William Montagna (USA)

VICE-PRESIDENTS

Fancis John Ebling (England)
Emiliano Panconesi (Italy)
Rodolfo Paoletti (Italy)

SECRETARY-GENERAL

Pierfrancesco Morganti (Italy)

PROGRAM DIRECTOR

M. Brodie James (USA)

BOARD OF TRUSTEES

Pierre Agache (France)
Fritz Kemper (Germany)
Lawrence Parish (USA)
W.E. Parish (England)
Wolfgang Raab (Austria)
Salvatore Randazzo (Italy)
Hans Schaefer (France)

ADVISORY BOARD

William Abramovitz (Venezuela)
Mohamed Amer (Egypt)
Ruben David Azulay (Brasil)
Claude Benezra (France)
I.A. Bernstein (USA)
O. Binet (France)
Otto Braun-Falco (Germany)
Peter Fritzch (Austria)
J. Morton Gillespie (Australia)
Marwall Harahap (Indonesia)
Vaino Hopsy-Havu (Finland)
Stephanie Jablonska (Poland)
A. Jarret (England)
Jon Kabara (USA)
F. Kardel Vegas (Venezuela)
Ch.M. Lapiere (Belgium)
Juhlin Lennart (Sweden)
R.S. Lester (Canada)
Howard Maibach (USA)
Ronald Marks (Wales)
Jose Mascaro (Spain)
J.P. Ortonne (France)
G.E. Pierard (Belgium)
Jaime Rubin (Argentina)
Wolfgang Rupilius (Germany)
Raul Vignale (Uruguay)
Jacques Wepierre (France)
Chu-Kwan Wong (Taiwan)

Trimestrale di Dermatologia Cosmetologica Quarterly Review of Cosmetic Dermatology

EDITOR

P. MORGANTI
PhD.
SECRETARY GENERAL
INTERNATIONAL SOCIETY of COSMETIC DERMATOLOGY
Via Innocenzo XI, 41 - 00165 Roma - (Italy) - Fax 06/63.80.839

ASSOCIATE EDITOR

S.D. RANDAZZO
M.D.
Professor of EXPERIMENTAL DERMATOLOGY
UNIVERSITY OF CATANIA
Via Iacona, 7 - 95124 Catania (Italy)

ASSISTANT EDITOR

M.B. JAMES
M.D.
PROGRAM DIRECTOR
INTERNATIONAL SOCIETY of COSMETIC DERMATOLOGY
JAMES CLINIC
34 Foreside Common Falmouth, Maine 04105 USA - Fax 001-207-7755182

EDITORIAL ADVISORY BOARD

P. AGACHE	MD, Prof. of Dermat. Centre Hosp. Regional de Besançon (F)
G. BELLOMONTE	CChem, Prof. of Chem., Food Depart Ist. Sup. Sanità - Roma (I)
W.F. BERGFELD	MD, FACP Cleveland Clinic Ohio (USA)
B. BERRA	DSc, Prof. of Biol. Chem. Univ. of Milano (I)
R. CAPUTO	MD, Prof. and Chairman, Depart. of Dermat. Univ. of Milano (I)
O. CARLESIMO	MD., Prof. and Chairman Depart. of Dermat. Univ. of Roma (I)
D. CERIMELE	MD, Prof. and Chairman, Depart. of Dermat. Univ. of Sassari (I)
E. CHIACCHIERINI	CChem, Prof. and Chairman, Depart. Techn. of Commerce Univ. of Roma (I)
J. COTTE	DSc, Prof. of Cosmet. IPIL Lyon (F)
M.A. DINA	MD, Prof. and Chairman, Depart. of Patol. Anat. Catholic. Univ. of Roma (I)
F.J.G. EBLING	DSc, PhD, Prof. of Zoology Univ. of Scheffeld (GB)
G. FABRIZI	MD, Paediatric Dermatologist, Catholic University of Roma (I)
A. FIDANZA	DSc, Prof. and Chairman, Depart. of Physiol. Univ. of Roma (I)
D. GRAFNETTER	PhD, Inst. for Clinical and Exp. Medicine Prague (CS)
J.A. GRAHAM	B.Sc, PhD, Dept. Dermatology Univ. of Pennsylvania (USA)
B. GUARNIERI	MD, Prof. and Chairman, Depart. of Dermat. Univ. of Messina (I)
A.J. JOUHAR	M.B.MRSC Beaconsfield (GB)
F.H. KEMPER	MD, Prof. and Chairman, Depart. of Pharmacol. and Tox. Univ. Munster (D)
A.M. KLIGMAN	MD, PhD, Prof. of Dermatol. Univ. of Pennsylvania Philadelphia (USA)
N. LOPRIENO	DSc, Prof. of Genetica Univ. of Pisa (I)
S. MADDIN	MD, ERCP Clin. Prof. Dermatol. Div. Dermat. Univ. BR. Columbia, Vancouver (C)
G. MAZZONE	MD, Prof. and Chairman, Depart. of Pharmacol. and Tox. Univ. of Catania (I)
C.L. MENEGHINI	MD, Prof. and Chairman, Depart. of Dermat. Univ. of Bari (I)
W. MONTAGNA	DSc, Prof. of Dermat. Oregon Health Science University (USA)
L. MUSCARDIN	MD, Prof. of Dermat. Centre Hosp. Regional IDI Roma (I)
N. ORENTREICH	MD, Clin. Prof. of Dermat. New York (USA)
E. PANCONESI	MD, Prof. and Chairman, Depart. of Dermat. Univ. of Firenze (I)
R. PAOLETTI	MD, Prof. and Chairman, Depart. of Pharmacol. and Tox. Univ. of Milano (I)
W.E. PARISH	MA, PhD, BVSc, Head of Environmental Safety Division, Unilever Research Schan brook (GB)
G. PROSERPIO	CChem, Prof. Inc. of Cosmet. Chem. Univ. of Torino (I)
L. PUGLISI	DSc, Prof. of Pharmacognosy Univ. of Milano (I)
V. QUERCIA	CChem, Prof. of Chem. Depart. of Pharm. Chem. Ist. Sup. Sanità Roma (I)
W. RAAB	MD, Prof. and Chairman, Depart. of Dermat. Univ. of Wien (A)
G. RABBIOSI	MD, Prof. and Chairman, Depart. of Dermat. Univ. of Pavia (I)
A. REBORA	MD, Prof. and Chairman, Depart. of Dermat. Univ. of Genova (I)
V. RIZZA	Ph.D. Prof. of Biol. Chem. Univ. of Catania (I)
G. SALVATORE	CChem, Depart. of Toxicol. Ist. Sup. Sanità Roma (I)
A. SANNA	MD, Prof. and Chairman, Depart. of Microbiol. Catholic. Univ. of Roma (I)
P. SANTOIANNI	MD, Prof. and Chairman, Depart. of Dermat. Univ. of Napoli (I)
H. SCHAEFFER	MD, PhD, Prof. and Chairman, Depart. of Pharmacol. CIRD Sophia-Antipolis Valbonne (F)
F. SERRI	MD, Prof. and Chairman, Depart. of Dermat. Catholic. Univ. of Roma (I)
A. SERTOLI	MD, Assoc. Prof. of Allergic and Occupational Dermat. Univ. of Firenze (I)
A. STAMMATI	DSC, Depart. of Toxicol. Ist. Sup. Sanità of Roma (I)
I. TADDEI	B.Sc., Prof. and Chairman, Depart. of Pharmacol. Science Univ. of Siena (I)
H. TRONNIER	MD, Prof. and Chairman, Depart. of Dermatol. Städtischen Kliniken of Dortmund (D)
V. VALKOVIC	CChem, Prof. of Physic Ruder Boskovic' Inst. of Zagreb (Y)

GENERAL INFORMATION

The **JOURNAL OF APPLIED COSMETOLOGY** is an international journal devoted to publishing original papers, reviews and other material which represent a useful contribution to research on the skin and on cosmetics.

It is aimed at cosmetic chemists, dermatologists, microbiologists, pharmacists, experimental biologists, toxicologists, plastic surgeons, and all other scientists working on products which will come into contact with the skin and its appendages.

The Journal is published quarterly in English. It is distributed to cosmetic chemists, dermatologists, plastic surgeons, medical and pharmaceutical schools, medical libraries, selected hospitals and research institutions throughout the world, and by subscription to any other interested individuals or organizations. Statements and opinions expressed are personal to the respective contributors and are not necessarily endorsed by the Editor(s), Advisers, Publishers or Distributors of this Journal.

COPYRIGHT

Submitted material must be the original work of the author(s) and must not have been submitted for publication elsewhere.

By submitting a manuscript, the authors agree that the copyright for their articles is transferred to the publisher if and when the article is accepted for publication. None of the content of this publication may be reproduced in whole or in part, translated, stored in a retrieval system, or transmitted or distributed in any form or by any means (electronic, mechanical, photocopy, recording or otherwise) without the prior written permission of the Publishers.

Sections of Journal

The following sections will be features of the Journal:

Original Laboratory Studies: descriptions of original investigative laboratory research in cosmetics and related areas.

Special Reports: Items of special interest to the readers, including reports on meetings, societies, legislation, etc.

General Articles: scientific articles of general interest to our readers will be considered for publication. These articles should be concerned with newer developments in such related fields as dermatology, biology, toxicology, etc.

Short Communications: the length should not exceed 5 typewritten pages with not more than 3 figures included. Headings ("Materials", "Discussion", etc.) as well as Summaries are to be omitted. If accepted, these submission will appear in print in a very short time.

Letter to the Editor: comments on Journal articles are invited as well as brief contributions on any aspects of cosmetic science. Letters may include figures, and/or references, but brevity is necessary.

Guest Editorials: concise, authoritative, substantiated commentary on specific topics of contemporary interest.

Book Reviews: book and monographs (domestic and foreign) will be reviewed depending on their interest and value to subscribers. Send material for review to the Editor, Dr. P. Morganti. No such material will be returned.

Address: all papers should be submitted to:
Dr. P. Morganti
INTERNATIONAL EDIEMME
Via Innocenzo XI, 41
00165 Rome - Italy
Tel. 06/637.87.88

INFORMATION FOR AUTHORS

Papers must be submitted in English. Authors whose mother tongue is not English should arrange for their manuscripts to be written in proper English prior to submission.

Procedure of Submission of Manuscripts: submit three copies of both the manuscript and all illustrative material to the above address.

Organization of the Manuscript: investigative studies should be organized as follow: title, abstract page, introduction, material and methods, results, discussion, acknowledgments, references, legend for figures, tables. All pages should be numbered consecutively starting with the abstract. The entire manuscript is to be typewritten, double-spaced, and with 3 cm margins.

Trade names must be capitalized: the common name for compounds may be used if the formal chemical name as established by international convention is given after the first use. Any abbreviations other than those which are generally accepted must be defined. In the text, references to dual authors will use both surnames throughout. For multiple authors, use the surnames of all authors at the first reference and only the first author followed by "et al." thereafter. Please mark in the margin of the manuscript the desired position of the figures and tables. To allow faster publication, only set of proofs will be furnished to the author including the figures and tables in their final position.

Title page: list the title, name(s) and degree(s) of author(s), department(s) and institution(s) at which the work was done, city, state, and postal code. Any preliminary report or abstract of the work should be referred to as a footnote to the title.

Summary: each paper must be headed by an English language title of not over 70 characters (including spaces) suitable for use as a running head and must also be preceded by an English summary not exceeding 300 words typed double-spaced. The summary will include statements of the problem, method of study, results, and conclusions. Since this summary will be used by abstracting journals, it must be self-explanatory and should not include abbreviations, footnotes, and references.

Footnotes: should be listed consecutively at the bottom of the page on which they fall, designated by the following symbols in order *, +, §, II, **, etc.

Key Words: key words for computerised storage and retrieval of information should be incorporated in the summary.

References: the references have to be abbreviated as listed in the Index Medicus. The style of the references must conform to the examples given below:

- 1) Robbins CR, Kellych (1970) Aminoacid composition of human hair. Text Res J 40:891-896
- 2) Strehler BL (1977) Time, cells and aging 2nd edn. Academic Press, New York
- 3) Ebling FJ, Rook (1972) Ciclic activity of the follicle. In: Textbook of dermatology 11, Blackwell, Oxford, p. 1567-1573.

Illustrations: figures should be numbered consecutively using Arabic numerals Tables should be numbered consecutively, using Roman numerals. All photographs should be black and white, glossy and unmounted. The number and size of illustration should be restricted to the minimum needed to clarify the text. Authors requiring extra space for illustrations will be charge accordingly. This is also the case for color illustrations. All figures, photographs, graphs, or diagrams should be submitted on separate sheets.

Animal Experiments: descriptions of animal experiments should include full details of the types of animal used (inbred, etc.) and the conditions under which they were kept (standard diet, etc.).

Trade Names: all common cosmetic ingredients should be referred to by their generic names, as indicated in the latest edition of CTFA Cosmetic Ingredient Dictionary, and the European Pharmacopeia. If a materials is not listed, then the trademarked name can be used, with the chemical composition given in footnotes.

INFORMAZIONI PER L'ABBONAMENTO

L'abbonamento annuale comprende quattro numeri. È possibile ottenere abbonamenti a prezzo ridotto da parte dei ricercatori che lavorano presso Istituti che abbiano sottoscritto almeno un abbonamento a prezzo normale.

L'Editore potrà fornire a richiesta notizie più dettagliate. Le sottoscrizioni di abbonamento possono essere effettuate mediante assegni postali, bancari, di conto corrente o per contanti indirizzandoli a:

L'IVA è a carico dell'editore, non detraibile dall'abbonato a norma art. 74 lett. C DPR 633/72

INTERNATIONAL EDIEMME - Via Innocenzo XI, 41, 00165 ROMA
(c/c bancario n. 29612/2 Banco di Santo Spirito Ag. 23, Roma)

SOTTOSCRIZIONI ANNUALI

Italia L. 60.000 - Altre Nazioni \$ 50

Numero singolo L. 16.000

Numero arretrato L. 20.000

Per la pubblicità di questa rivista:

Concessionaria Italiana Pubblicità G & V s.r.l.

Via Savona, 94 - 20144 Milano - Tel. (02) 48952587-48952874

SUBSCRIPTION INFORMATION

Subscriptions are entered on a calendar years basis only and include four regular quarterly issues. Half-price subscriptions are available to research scientists whose institutions already subscribe at full rate. Details on application from publisher. Payment must be made in U.S. dollars using bank draft, international postal money order only. Italian residents only may pay by personal check:

INTERNATIONAL EDIEMME - Via Innocenzo XI, 41, 00165 ROMA
(c/c bancario n. 29612/2 Banco di Santo Spirito Ag. 23, Roma)

ANNUAL SUBSCRIPTION RATE:

Italy, Lit. 60.000 - Other Countries, \$ 50

Additional Air Mail postage rate: Africa and Middle East \$ 12. North, Central and South America \$ 14, Far East \$ 15, Oceania \$ 19.50

Statements and opinions expressed in the articles and communications herein are those of the author(s) and not necessarily those of the Editor(s), or publisher. The Editor(s) and publisher, disclaim any responsibility or liability for such material and do not guarantee, warrant, or endorse any product or service advertised in this publication nor do guarantee any claim made by the manufacturer of such product or service

STAMP

Spett. Direzione

**“JOURNAL OF APPLIED COSMETOLOGY”
INTERNATIONAL EDIEMME
Via Innocenzo XI, 41
00165 ROMA (ITALY)**

STAMP

Spett. Direzione

**“JOURNAL OF APPLIED COSMETOLOGY”
INTERNATIONAL EDIEMME
Via Innocenzo XI, 41
00165 ROMA (ITALY)**

Trimestrale di Dermatologia Cosmetologica

Quarterly Review of Cosmetic Dermatology

Contents

General Articles

- 1** Use and efficacy of urea in dermatological preparations
W. Wohlrab

- 9** Urea from the chemist's point of view
R. P. Raab

- 15** Biochemistry, pharmacology and therapeutic use of urea
W. Raab

Original Laboratory Studies

- 19** Changes in stratum corneum after urea application to human skin in vivo.
Electron microscopic investigation
G. Stüttgen

- 24** Book Review

XIX Announcements

4th International Meeting of International Society of Cosmetic Dermatology
"Progress in Cosmetic Dermatology: Science and Safety"
Rome - Italy October 30-November 2, 1991
Preliminary Program

18th World Congress of Dermatology

USE AND EFFICACY OF UREA IN DERMATOLOGICAL PREPARATIONS

W. Wohlrab

Department of Dermatology, Martin-Luther-University, PSF 302-D-4010 Halle

Received: October 26, 1989; Presented at 3rd International Congress on Cosmetic Dermatology "Progress in Cosmetic Dermatology" - 27 - 29th October 1989, Wien

Key words: Urea; Penetration; Water-binding capacity; Topical therapy.

Synopsis

The basis of the effects of urea on the human skin is its penetration kinetics into different skin layers. A strong vehicle dependence can be established. Therefore wide differences are found in the duration and intensity of increased water-binding capacity after application of different urea containing emulsions. For therapy to increase the hydration and water-binding capacity in the horny layer of diseased skin preparations with 10% urea are more suitable than those containing 2% or 5% urea. For cosmetic preparations, the higher concentrations of urea are inappropriate, lower ones are sufficient. By altering the functional structure of the horny layer and increasing of drug liberation from ointment bases, urea is one of the most effective penetration promoters. An increased penetration rate of some corticosteroids, dithranol and other drugs in human skin. The resulting penetration has two possible implications for topical therapy:

- an increased therapeutic effect for any given concentration of an active constituent
- the attainment of a given therapeutic effect with a reduced concentration of the active ingredient.

Riassunto

Gli effetti esplicati dall'urea sono connessi alla sua penetrazione attraverso i differenti strati dell'epidermide e, quindi, direttamente dipendenti dal tipo di veicolo utilizzato. Per questi motivi sono state riscontrate differenze nella durata e nella intensità della capacità del prodotto di legare acqua in dipendenza del tipo di emulsione. Per incrementare l'idratazione cutanea e la capacità di legare acqua della cute affetta da patologie si sono dimostrate più efficaci concentrazioni di urea del 10% rispetto a concentrazioni del 2 o del 5%. Per uso cosmetico sono più adatte e sufficienti concentrazioni basse di urea.

L'urea può essere considerata una delle sostanze più attive nel promuovere la liberazione dei farmaci dai veicoli e, quindi, il loro assorbimento. Facilita, perciò, l'attività dei corticosteroidi, del ditranolo e di molti altri farmaci.

Queste sue caratteristiche ne consigliano l'uso terapeutico in due direzioni diverse:

- per incrementare l'effetto terapeutico di una data concentrazione di farmaci resi per questi motivi ugualmente attivi a concentrazioni più basse.

The use of urea in topical therapy and in cosmetics has undergone a revival in recent years (1, 3, 4, 11 and others).

Some reasons for this can be listed as follows:

1. By intensive basic research many properties of urea have been discovered and precisely defined. At the same time, the conditions for the therapeutic utilization of these properties e.g. problems of stabilization, have been delineated.

2. In topical therapy increasing use is made of pharmacokinetic information. The equal significance of the properties of the active substances and of the vehicle, the condition of the skin, and their mutual interactions, are not only recognized but also increasingly utilized a basic for overall therapeutic activity. Pharmaceutical formulations are selected and optimized in such a way that a desirable concentration/time profile is achieved for the substance in the appropriate skin layer.

3. The properties of urea itself make it ideal for external use, as it is a natural moisturizer and is well tolerated. As a physiological substance it is the end product of protein metabolism. In human skin its concentration is 1% and it is excreted in sweat in considerable quantities. After external or systemic administration it is not metabolized. No side effects, in particular non cases of sensitization or photosensitization, have so far been reported under therapeutic conditions.

Principles of the action of urea on skin

The penetration kinetics of urea, i.e. how much urea, in relation to exposure time, penetrates into individual skin layers after external application, are of decisive importance to the achievement of its effects. In relation to the vehicle, the penetration kinetics of urea show

fundamental differences between w/o and o/w emulsions (7), and these yield different therapeutic effects.

Urea penetrates the horny layer of human skin more quickly from o/w emulsions than from w/o emulsions (Fig. 1). It should be noted that, at about 80%, the bulk of the urea which has penetrated is found in the upper horny layers.




FIGURE 1

Distribution of urea in the horny layer of human skin after external application of 10% urea containing preparations.

---•• w/o-emulsion (Ungt. Alcohol. Lanæ aquosum, Pharmacopoea GDR)
—○— o/w-emulsion (Ungt. emulsificans aquosum, Pharmacopoea GDR)

The steep concentration gradient is largely maintained when o/w emulsions are used, even after as long as 1000 min.

In contrast, the penetration of urea from w/o emulsions is noticeably smaller after short exposure. The concentration gradient within the horny layer decreases so that after 1000 min approximately equal urea concentrations can be measured throughout the stratum corneum.

This results in different urea concentrations in the epidermis and dermis (Fig. 2), which are appreciably higher for w/o emulsions. Overall, however, the penetration of the lower epidermis and dermis are small in comparison with that of the horny layer, regardless of the emulsion used.




FIGURE 2

Distribution of urea in human skin after external application of 10% urea containing preparations.

• - - - • w/o-emulsion (Ungt. Alcohol. Lanae aquosum, Pharmacopoea GDR)
 o — o o/w-emulsion (Ungt. emulsificans aquosum, Pharmacopoea GDR)

These differences in the course of penetration and hence in the concentration/time profile of urea in the individual skin layer provide for different degrees of efficacy. Different emulsions can be used according to whether the urea is to act on the functional skin structure (e.g. hydration and water-binding capacity, keratolysis, inhibition of proliferation, alleviation of itching, etc.) or to aid penetration by other products.

What is the necessary concentration of urea in the vehicle?

From the findings so far discussed, it is clear that the decisive factor in therapeutic activity is not the concentration of urea in the applied vehicle but rather the quantity of urea which penetrates into the individual skin layers, i.e. the concentration/time profile achieved. It has be

Table I

CONCENTRATION OF UREA PENETRATING TO THE STRATUM CORNEUM (SC) OF HUMAN SKIN IN RELATION TO THE CONCENTRATION OF UREA IN THE VEHICLE (9)

Vehicle: W/O-emulsion (Ungt. Alcohol. Lanae aquosum AB-DDR)

Penetration Period (min)	Urea Concentration (%) applied	Urea concentration (mm) in the sc
30	2	29,9
	5	103,1
	10	212,6
300	2	48,3
	5	145,7
	10	449,9
1000	2	95,8
	5	231,6
	10	602,9

noted that, at around 80%, the bulk of the urea which penetrates is situated in the outer horny layers (Tab. 1). When vehicles containing 2% or 5% are used the urea concentration necessary for normal human stratum corneum cannot be reached. To increase the water-binding capacity in the horny layer of diseased skin products containing 10% of urea are more suitable from the therapeutic point of view (9). High urea concentrations (over 2-3%) are not, however suitable for cosmetic use without medical supervision.

Influence of the vehicle on the water-binding capacity due to urea.

Corresponding to the described differences in penetration, depending on the vehicle and the urea concentrations used, there are also variations in the effectiveness of the urea-containing basic skin products to increase the water-bind-




FIGURE 3

Influence of urea on the water-binding capacity of the human horny layer (10).

Vehicle: w/o-emulsion (Ungt. Alcohol. Lanae aquosum, Pharmacopoea GDR) labeled with tritiated water.

ing capacity of the stratum corneum (5, 6). When the urea is used in o/w emulsions or lotions, a high degree of hydration is quickly reached (immediate effect), but this fairly quickly declines (Fig. 3).

In contrast, with w/o emulsions there is a more marked and longer-lasting increase in water-binding capacity.

Table II

WATER-BINDING CAPACITY OF HUMAN HORNY LAYER AFTER APPLICATION OF UREA CONTAINING PREPARATIONS (10).

Application: 10 mg of urea containing preparation labeled with 5 μ Ci tritiated water at 4 cm² skin surface.

preparation	urea concentration (%)	Horny layer dpm/cm ² after		
		30	300	1000 min
Basodexan (R) Ointment	10	5422 $\pm$ 521	2478 $\pm$ 205	902 $\pm$ 51
Basodexan (R) Cr��m��	10	8104 $\pm$ 514	1386 $\pm$ 169	472 $\pm$ 34
Basodexan (R) Soft	10	10606 $\pm$ 678	542 $\pm$ 98	185 $\pm$ 22
Carbamid-Cr��m��(R)	12	8666 $\pm$ 426	1214 $\pm$ 100	475 $\pm$ 28
Elacutan-F(R)	10	3968 $\pm$ 275	994 $\pm$ 63	678 $\pm$ 74
Elacutan-W(R)	10	7185 $\pm$ 376	426 $\pm$ 72	183 $\pm$ 19
Excipial(R)-U-Lotio	2	6804 $\pm$ 248	388 $\pm$ 26	126 $\pm$ 24
HTH(R)	10	12011 $\pm$ 528	568 $\pm$ 59	223 $\pm$ 63

If one examines these basic mechanism in relation to the various commercial urea-containing basic skin products, large differences are found in the action on the water-binding capacity of the stratum corneum (Tab. 2). These differences are evidently not primarily dependent on the urea concentration used but on the vehicle (10).

Influence of urea on the penetration of other products

Urea promotes the release of various drugs from their base, and in addition it is a very effective promoter of penetration of various active substances (1, 3, 4, 11). Essentially, the promotion of drug penetration by urea can be exploited in two ways (8):

1. to improve therapeutic efficacy at the same concentration of active substance and
2. to achieve the same therapeutic efficacy with a considerably lower concentration (Fig. 4).

The optimization of the therapeutic efficacy of other drugs by urea has been demonstrated

above all with glucocorticoids (e.g. Hydrodexam (R), Hycozon (R), Alphaderm (R), etc.) and dithranol (e.g. Psoradexan (R)), with impressive evidence from numerous clinical studies.

With respect to hydrocortisone, it has been shown that when low concentrations of urea are used enhancement of penetration is barely apparent, whereas with a urea content of between 5% and 10% there is a particular increase (Fig. 5).




FIGURE 5

Dependence of hydrocortisone penetration into epidermis of human skin on urea concentration and used vehicle.

Penetration time: 300 min.

Hydrocortisone concentration: 1%.

• - - - w/o-emulsion (Ungt. Alcohol. Lanæ aquosum, Pharmacopoea GDR)

o o o/w-emulsion (Ungt. emulsificans aquosum, Pharmacopoeia GDR)




FIGURE 4

Distribution of hydrocortisone (HC) in human skin after external application (8).

When the urea concentrations are raised further, no further decisive changes are detectable. In this connection o/w emulsions and w/o emulsions basically act in the same direction, but w/o emulsions have a considerably greater penetration-promoting effect.

On the basis of these data hydrocortisone, the determination of the penetration kinetics of the glucocorticoid and of the urea in each vehicle is indispensable for making use of the penetration-promoting action of urea in the development of

glucocorticoids for external use (8). The urea and glucocorticoid concentrations can then be optimized.

Less attention has so far been paid to the possibility of using the penetration-promoting action of urea to achieve a particular therapeutic efficacy with a considerably reduced quantity of glucocorticoid. One reason is very probably the widely practised dilution of proprietary glucocorticoid formulations. In 1984 Müller (2) summarized the reasons for this procedure and its problems and risks in a very informative review. The example of hydrocortisone shows very clearly that after reduction to 0,5% the quantity which penetrates e.g. into the epidermis can be reduced by 75-80% (Tab. 3). In contrast, when various quantities of urea are added, a concentration-dependent promotion of penetration is detectable, so that the formulation

becomes identical in efficacy with a 1% hydrocortisone product in which there is no urea.

Viewing this subject as a whole, we still know too little about the pharmacological properties of urea for external use. Automatic procedures in the application of urea in external therapy and examination of the properties of urea in isolation therefore promise little success and should be avoided.

Table III

INFLUENCE OF UREA ON THE PENETRATION OF REDUCED HYDROCORTISONE CONCENTRATIONS INTO HUMAN SKIN (12).

Vehicle: W/O-emulsion (Ungt. Alcohol. Lanae aquosum, Pharmacopea GDR)

HC = hydrocortisone; U⁺ = Urea.

Preparation	penetration time (min)	
	30	300
horny layer (mmol)		
1,0% HC	13,9	16,1
0,5% HC	2,9	3,9
0,5% HC + 5% U ⁺	8,5	10,0
0,5% HC + 10% U ⁺	12,5	13,8
0,5% HC + 15% U ⁺	12,8	14,0
epidermis (μmol)		
1,0% HC	12,8	23,2
0,5% HC	2,1	5,7
0,5% HC + 5% U ⁺	6,8	11,0
0,5% HC + 10% U ⁺	10,2	19,9
0,5% HC + 15% U ⁺	11,9	20,7

References

1. Horsch W., Wolf B. (1985): Harnstoff. Eine Übersicht unter Besonderer Berücksichtigung seiner pharmazeutischen Verwendung und Analytik. *Pharmazie* **40**, 665-676.
2. Müller K.H.(1984): Corticoid-Verdünnungen. *Zbl. Haut-und Geschlechtskrankh.* **149**, 853-861.
3. Müller K.H., Pflugshaupt Ch. (1979): Harnstoff in der Dermatologie. *Zbl. Haut-und Geschlechtskrankh.* **142**, 157-168.
4. Müller, K.H., Ch. Pflugshaupt (1989): Harnstoff in der Dermatologie. II. *Ergänzende Literaturübersicht. Hautarzt* **40**, Suppl. IX, 13-19.
5. Stüttgen, G. (1988): Der Begriff "Trockene Haut" aus patho-physiologischer Sicht.*Z. Hautkr.* **63** (Suppl. 3), 7-11.
6. Thiele F.A.J.,Reay D.A.,Mali J.W.H.,De Jongh G.J. (1981): The water balance of the horny layer and the functional characteristics of the atrichial sweat glands of human skin. In: Handbuch der Haut-und Geschlechtskrankh., Ergänzungswerk, 1. Band, Teil 4B; Normal and Pathologic Physiology of the Skin. Hrsg.: Stüttgen, G. Spier, H.W. und Schwarz, E.: Berlin-Heidelberg-New York: Springer-Verlag 1981.
7. Wohlrab W. (1984): Vehikelabhängigkeit der Harnstoff-Penetration in die menschliche Haut. *Dermatologica* **169**, 53-59.
8. Wohlrab W. (1984): The influence of urea on the penetration kinetics of topically applied corticosteroids. *Acta Dermato-Venereol. (Stockh.)* **64**, 233-238.
9. Wohlrab, W. (1988): Welche Harnstoffkonzentration ist für die externe Therapie notwendig. *Dermatol. Mon.schr.* **174**, 94-98.
10. Wohlrab, W. (1988): Der Einfluß von Harnstoff auf die Wasserbindungskapazität der menschlichen Hornschicht. *Dermatol. Mon.schr.* **174**, 622-627.
11. Wohlrab, W. (1989): Bedeutung von Harnstoff in der externen Therapie. *Hautarzt* **40**, Suppl. IX, 35-41.
12. Wohlrab W., Taube K.M., Kuchenbecker I. (1990): Penetration und Wirksamkeit von Hydrokortison bei reduzierter Konzentration im Vehikel. *Z. Hautkrankh.* **65**, 534-537.

UREA FROM THE CHEMIST'S POINT OF VIEW

Regina P. Raab, M.D.

2nd department of Dermatology Vienna University Medical School, Austria

Received: October 26, 1989; Presented at 3rd International Congress on Cosmetic Dermatology "Progress in Cosmetic Dermatology" - 27 - 29th October 1989, Wien

Key words: Urea; Chemistry; Manufacture; Decomposition; Stabilization; Recommended Concentrations

Synopsis

Urea is a colourless and odourless tetragonal crystal. Due to its molecular structure (dipolaric) it can easily be dissolved in water, whereas it is almost insoluble in nonpolar substances such as chloroform or ether. In solution, urea undergoes a decomposition to carbon dioxide and ammonia. A so-called "sand paper effect" may occur, especially in preparations containing higher urea concentrations caused by the phenomenon of recrystallisation.

Therefore topical products with urea require stabilisation (either with triacetin, lactic acid or polysaccharides). Non stabilised urea containing preparations can only be used safely for periods of up to six weeks (the stabilised preparations can be stored for two or even three years).

In conclusion it can be said that urea containing formulations for cosmetic and/or dermatological purposes have to be developed with great care to provide perfect results.

Riassunto

L'urea é una sostanza cristallina e inodore, facilmente solubile in acqua e praticamente insolubile nei solventi apolari quali il cloroformio e l'etere. Una volta disciolta l'urea si decompone facilmente in anidride carbonica ed ammoniaca.

Data la sua poca stabilità in soluzione i preparati topici a base di urea debbono essere ben stabilizzati (sia con acido lattico che con polisaccaridi).

Si deve fare anche molta attenzione alla sua concentrazione di utilizzo per evitare il fenomeno di ricristallizzazione che provoca il cosiddetto "effetto sabbia" ben noto agli utilizzatori abituali. In conclusione si può affermare che le preparazioni cosmetiche o dermatologiche a base di urea debbono essere formulate e controllate con grande cura.

Introduction

Jean Rouelle (1718-1778), a french apothecary, discovered urea as a natural constituent of human urine in 1773 ("Identification d'une substance savonneuse dans l'urine"). Friedrich Wöhler (1800-1882), M.D. and chemist, succeeded in synthesizing urea from ammonium cyanate. He therefore proved that no mystical "vis vitalis" is necessary to synthesise organic materials from inorganic precursors.

Manufacture and chemistry of Urea:

Urea (U) is the diamide of carbonic acid. It is a colourless, odourless (or nearly odourless), slightly hypogrosopic prismatic crystalline substance with a cooling saline taste (2).

The world production of urea is mainly used in fertilizers and for the synthesis of plastics (altogether 40 million tons in 1980).

These large amounts of U are manufactured from ammonia and carbon dioxide under high pressure (100-200 atm) and high temperatures (170-250°C). In the laboratory U is still synthesized by the method of Dr. Wöhler.

Apart from the many favourable effects of topical urea, this substance is cheap. 1 kg of Urea pura of the quality specified in the Austrian pharmacopoeia would cost less than 50 AS.

Due to its ability to form intramolecular dipoles, U resembles the water molecule. Therefore it readily dissolves in polar solvents such as water or alcohol but it is almost insoluble in nonpolar media such as chloroform or ether.

U is a weak acceptor of protons and would give in water a solution with a pH of 7.5, at least theoretically. Deviations occur due either to the carbon dioxide content of water or to impurities and decomposition of U itself.

Decomposition of urea (Fig. 1)

Once in solution, urea decomposes and, in simple terms, the following reactions occur. First U is converted into ammonium cyanate. The equilibrium lies completely on the side of the unchanged U. In the subsequent reaction ammonium cyanate is hydrolytically split. Other U molecules then form ammonium cyanate in order to maintain the equilibrium of the first reaction. Ammonium cyanate is split into two molecules of ammonia and one molecule of carbonic acid. Carbonic acid is a weak and instable acid ($\text{H}^+ + \text{HCO}_3 \rightleftharpoons \text{H}_2\text{CO}_3 \rightleftharpoons \text{CO}_2 + \text{H}_2\text{O}$), the two molecules of ammonia react as proton (H^+)- acceptors.




FIGURE 1

Therefore the pH constantly increases.

Some factors such as the steadily increasing pH, raising of the temperature and open storage, which permits the escape of the produced ammonia and carbon dioxide, enhance the decomposition. Open storage (and high temperature in addition) favours evaporation of water. The result could be a recrystallization of U. The risk is greater with the higher initial concentrations of U. The crystals act like sand on the skin and cause irritation.

Therefore topical preparations containing urea should be made airtight after each usage and stored at normal room temperature or below. Before application it should be made sure that no sandiness has developed (4).

Stabilization of Urea:

The above mentioned facts explain why industrially produced topical preparations containing urea must be stabilized.

Stabilization reduces and delays disintegration and keeps the pH constant over longer periods (2).

One possibility for stabilizing U is the addition of triacetin. Triacetin is an ester of glycerol with three molecules of acetic acid. As soon as pH increases, the ester bonds are hydrolytically split and the released acetic acid will keep pH constant. Another possibility is the addition of lactic acid, which is as effective as acetic acid. Moreover, lactic acid is part of the NMF of the skin and will therefore increase one of the effects of U. However stabilization with lactic acid can lead to burning sensations.

At present the most sophisticated method of stabilization is the adsorption of U to polysaccharides (for instance corn or rice starch). There are no problems with local tolerance, and the pH in these formulations can be adjusted as desired.

Urea containing preparations for topical use upon special prescription:

Some problems arise if one prescribes an U containing topical preparation. Generally spoken this task is easier the lower the required U concentrations and the higher the required water content are. Before introducing U into the formulation the crystals have to be pul-

verized. The use of an ointment mill will cause disappearance of sandiness (4).

For cosmetic and dermatological purposes such as augmentation of the skin-moisture, general skin protection and therapy of scaly lesions, 3-5% U in an O/W emulsion are recommended (5,6). This will have an immediate effect on the upper horny layers (Fig. 2 and 3).

UREA IN O/W

Urea purae	5,0
NaCl	5,0
Tween 80	20,0
Aquae dest.	40,0
Vas. alb. ad	100,0

FIGURE 2

UREA IN O/W

Urea purae	3,0
Allantoin	0,2
Karion F liqu.	3,0
Vas. flav.	10,0
Lanette N	15,0
Guajazulen 25%	0,04
Aquae dest.	100,0

FIGURE 3

For the treatment of pronounced dermatological disturbances such as psoriasis vulgaris, different forms of ichthyosis, atopic dermatitis and extremely dry skin, 10% U in W/O should be applied (5,6). U in W/O has not such a distinct immediate effect but has a longer lasting beneficial action due to its deeper penetration into the

skin (Fig. 4). For painless onycholysis, 40% U concentrations are necessary. The surrounding skin should be protected with a paste.

UREA IN W/O	
Urea purae	10,0
NaCl	10,0
Aquae dest.	20,0
Ungt. alc. lanae aqu. ad	100,0

FIGURE 4

After 5-10 days of occlusion the nail can be removed (7). As shown in Fig. 5, U in this case is incorporated into a vehicle, which consists only of various lipids. It is not dissolved but merely suspended. Therefore sandiness is inevitable. No improvement will be brought about by ointment mills as their use will lead to separation of the different parts of the vehicle (4).

ONYCHOLYSIS WITH UREA	
Urea purae	40,0
NaCl	5,0
Aquae dest.	20,0
Ungt. alc. lanae aqu. ad	100,0
Occlusion (5-10 d)	

FIGURE 5

Industrially produced urea containing preparations for topical use:

Industrially manufactured products have some distinct advantages over those upon special prescription. They have a guaranteed stability over 2-3 years on an average, whereas the prescribed products can only be used for 4-6

weeks. The quality of manufactured creams, ointments or lotions is good and constant.

Urea itself shows some antimicrobial action (5). Therefore little or no preservative need be added, and it is well known, that preservatives are rather disadvantageous from the allergological point of view.

In summary it can be said, that urea is a somewhat difficult substance to incorporate into good and stable topical formulations. Therefore urea containing preparations for cosmetological and dermatological purposes need to be developed with the utmost care to guarantee perfect results.

References

1. **Braun-Falco O, Plewig W. (1984):** Dermatologie und Venerologie, *Springer Verlag Berlin - Heidelberg - New York*. 3rd Edition, p. 1011
2. **Horsch W. et al (1985):** Harnstoff - Eine Übersicht unter besonderer Berücksichtigung seiner pharmazeutischen Verwendung und Analytik. In: *Die Pharmazie, Heft 10*, p. 665-676
3. **Österreichische Apothekerkammer (1988):** Neues Formularium Austriacum
4. **Raab R. (1989):** Harnstoffrezepturen. In: *Der Hautarzt 40*, Suppl. 8, p. 80-81
5. **Wohlrab W. (1988):** Zur Verwendung von Harnstoff in der Dermatologie. *D. Derm.* **36**: p. 528-537
6. **Wohlrab, W. (1988):** Welche Harnstoffkonzentration ist für die externe Therapie notwendig. *Dermatolog. Monatsschrift 174*, 94-98.
7. **Zesch A. (1985):** Externa, Galenik, Wirkungen, Anwendungen. *Springer Verlag Berlin - Heidelberg - New York*

BIOCHEMISTRY, PHARMACOLOGY AND THERAPEUTIC USE OF UREA

W. Raab

(Allergy Clinic "City", Vienna, Austria) 3, Walfischgasse A-1010 Vienna, Austria

Received: October 26, 1989. Presented at 3rd International Congress on Cosmetic Dermatology "Progress in Cosmetic Dermatology" - 27 - 29th October 1989, Wien

Key words: Urea; Safety; Preservatives; Atopic Eczema

Synopsis

Modern dermatology looks more and more closely into "old" substances which proved to be effective and safe. In addition, most of them are much cheaper than the new compounds. Urea is one of the old substances which were used more and more often in topical therapy of dermatoses, either alone or in combination with a steroid, anthralin, retinoic acid or salicylic acid. In this paper, biochemistry and pharmacology of urea with special reference to its topical application were outlined. In many dermatoses, urea containing preparations may be successfully applied. Lastly, the possibilities of urea in cosmetology are briefly discussed.

Riassunto

L'urea é una delle sostanze più vecchie di uso dermatologico, utilizzata in terapia da sola o in associazione con steroidi, atralina, acido retinoico e acido salicilico. Viene descritto l'aspetto biochimico e farmacologico dell'urea in relazione soprattutto al suo uso topico. In molte dermatosi le preparazioni a base di urea vengono utilizzate con grande successo. Infine ne viene discusso il suo uso cosmetologico.

Introduction

Urea (carbamide, the diamide of carbonic acid) may be found in all organs, tissues, and body fluids.

Physiologically, urea is present on the skin surface, too, as a component of the hydrolipid emulsion. Urea here stems from sweat (content 0.4% urea) and from keratinization (end product of arginine degradation).

In former times, urea mainly was used as a diuretic and an antiedema drug. Doses amounted to 15 g per day orally or 1.0 g/kg/d intravenously. Urea was well tolerated even in these high doses.

From the beginning of the forties, urea was used for dermatological therapy in the form of creams and ointments (1, 2, 4). Numerous experimental investigations proved its valuable therapeutic actions. In the last years, urea is also increasingly found in cosmetic preparations.

In December 1988, a symposium was held in Salzburg on "Urea in dermatology". The proceedings of this conference contain all the documentation on this topic (2).

Dermato-toxicology of urea

The topical use of urea never provokes systemic resorptive effects as urea by itself is an atoxic substance.

On healthy skin, urea may be applied in concentrations up to 20%. (Due to chemical factors, such concentrations are not easy to reach!). On inflamed skin, concentrations of urea should be limited to 2 or 10%, depending upon the state of the lesions. Urea in a 40% concentration may be used for chemical onycholysis, e.g. in onychomycoses.

Urea lacks sensitizing and photodynamic activities. Urea is color- and odorless and does not stain either the skin or the linen.

Pharmacological activities of urea upon topical use

Applied externally, urea exerts a variety of dermatologically and cosmetologically important actions:

Moisturizing action: Urea binds water by including it into its crystal structure. In a concentration of 70%, urea is an important component of the natural moisturizing factor of normal human skin. In contrast to the effects of humectants (glycerol, propylene glycol), urea acts a moisturizer even in xerotic skin conditions. As water is the most important plastifying agent in stratum corneum, humidity significantly improves smoothness of the skin. Atopic skin with its lack of water binding capacity needs urea for its care.

Keratolytic - keratinolytic action: By splitting hydrogen bonds, urea in high concentrations (40%) exerts a proteinolytic (keratinolytic) activity. This effect may be used for a chemical onycholysis.

Desquamating action: Urea loosens the intercellular connections between the corneocytes thus facilitating desquamation of superficial cells and, on the other hand, increasing penetration. This effect may activate of drugs which are applied concomitantly with urea.

Antimicrobial action: By absorbing water, urea hinders the growth of microorganisms, without provoking an antimicrobial effect in the usual sense. Thus, preservation of urea-containing products needs less potential allergens in the form of the usual microbistatic substances.

Antiinflammatory action: The antiinflammatory action of urea consists of several components: antiproliferative (in states of increased cellular turnover, only), antiedematous (topical

"diuretic" effect, as could be demonstrated in cases of lymphostatic papillomatosis cutis verrucosa), and antipruritic (inhibitory action on enzymatic activities which promote itch).

Dermatological indications for urea

Topical preparations containing urea may successfully be used in a variety of dermatoses:

- Atopic eczema (therapeutic application, skin care in states of dryness and various forms of subacute and chronic, dry eczemas.
- Psoriasis vulgaris and other scaly diseases.
- Senile skin and other states of excessive dryness and itch.
- Ichthyosis
- Hyperkeratoses, keratoses.
- Chemical onycholysis, e.g. in onychomycoses.

Urea combined with other drugs

By its desquamating and hydrating actions, urea increases the bioavailability of other drugs.

Furthermore, urea enhances the topical activity of some substances by influencing their solubility and crystal structure.

Urea can be successfully combined with the following substances:

- Glucocorticoids: The addition of urea increases the therapeutic activity of the glucocorticoids

without changing the extent of undesirable actions. E. g., 1% hydrocortisone reaches the therapeutic effectiveness of 0.025% fluocinonide when 10% urea is incorporated. In combination with glucocorticoids, the antimicrobial action of urea is of special importance.

- Anthralin: The addition of 17% urea to anthralin 0.05 - 0.2% improves the antisporiatic action, in short contact therapy as well as in day-time care. Irritation and staining by anthralin is diminished, so compliance is increased.

- Tretinoin: In severe ichthyoses, with the exception of the inflammatory and erythrodermatic forms, a combination of 0.03% tretinoin with 10% urea may be used. Such a product may also prove to be successful in stubborn cases of chronic psoriasis.

- Salicylic acid: In stubborn cases of hyperkeratoses, a combination containing 10% urea and 10% salicylic acid was recommended.

Urea is cosmetology

In cosmetic products, creams, ointments or - best - lotions, urea is incorporated for skin care purposes in concentrations between 2 and 5%. For cosmetic purposes, the moisturizing action of urea is of greatest importance. Skin care products for senescent people should contain urea. One may assume that the use of urea in cosmetic products will steadily increase (3).

References

1. Kligman A. M.: Dermatological uses of urea. *Acta Dermato-Venereol.*, Stockholm, **37**: 155-159, 1957
2. Raab W.: Harnstoff in der Dermatologie. *Hautarzt* **40**, Suppl. 9, 1989
3. Raab W.: Urea in cosmetology. *Cosmet. Toiletr.* **105**, 97-102, 1990
4. Wohlrab W.: Zur Verwendung von Harnstoff in der Dermatologie. *Der Deutsche Dermatologe* **36**: 528-537, 1988

CHANGES IN STRATUM CORNEUM AFTER UREA APPLICATION TO HUMAN SKIN IN VIVO. ELECTRON MICROSCOPIC INVESTIGATIONS

G. Stüttgen

Kissinger Strabe 12, D-Berlin 33

Received: October 26, 1989. Presented at 3rd International Congress on Cosmetic Dermatology "Progress in Cosmetic Dermatology" - 27 - 29th October 1989, Wien

Key words: Stratum Corneum Changes; Urea and Keratin; Electron Microscopic Investigation

Synopsis

Urea, 10% in cream or ointment, applied in vivo for 24 and 48 hours with part occlusion changes the inner structure of the horny cells, depending on time and the excipients. Splitting of the keratin changes the matrix and the osmiophilic behaviour, especially in the upper regions. After 48 hours fine granulation within the horny cells and enhancement of cavities can be demonstrated. There is no evidence of any changes in the osmiophilic material in the intercellular spaces. Urea does not enhance permeability per se, it increases the surface of the keratinous material and its capacity to bind water and other substances with low molecular weight.

Riassunto

L'applicazione topica mediante bendaggio parzialmente oclusivo di una crema o di un unguento al 10% di urea provoca modificazioni della struttura dello strato corneo, dipendente dal tempo di contatto e dal tipo di veicolo. Si osserva del materiale cheratinico con variazioni a livello delle matrici. Dopo 48 ore si osserva una fine granulazione delle cellule cornee con comparsa di cavità. Non si evidenziano cambiamenti degli spazi intercellulari. L'urea non facilita di per se la permeabilità ma aumenta la superficie del materiale cheratinizzato e la sua capacità di legare acqua e altre sostanze a basso peso molecolare.

Introduction

The influence of urea on the horny layer and the ensuing changes in function have been researched very carefully (1, 2, 3, 5). The external use of urea, incorporated into different bases, in dermatology and cosmetology depends on such data (6).

The changes in the structure of the horny layer after topical application of urea to human beings have not however, until now been examined electron microscopically, either in vivo or in vitro.

Stratum corneum can be divided into 3 layers (Orfanos 1981).

1. Flat horny cells in the basal zone having electron dense membranes which enclose the homogeneous relatively light material.

2. The middle zone consists of horny cells with an electron - dense network of different structures which can be interrupted by small cavities.

3. Finally the superficial zone is characterised by broad intercellular spaces and lack of desmosomes, which are visible as electron dense threads only in - the lower horny layer .

Tonofilaments and the hyaline granules are the material of which the keratin, in the form of bigger tonofibril hyalin complexes is composed. The formation of horny layer is a quick process, more or less a jump, into keratinisation.

Horny cells with an osmiophobic filaments, embedded in an osmiophilic matrix are known as A-cells. Horny cells with a pattern of osmiophilic filaments embedded in an osmiophilic matrix are classified as B-horny cells. The intercellular substance is formed by membrane coating granules (Odland-bodies) which are extruded into the intercellular space in the granular layer and form glycosphingolipids, ceramides, nonesterified sterols and fatty acids. This material forms the bilipid layers which as lamellar sheets surrounding the horny cells (4).

Methods

We took punch biopsies (2mm in diameter) after application of 10% urea in creams or ointment for 24 hours or 48 hours and examined them by electron microscopy.

For the first 24 hours occlusive dressings were used, subsequently the applications were lettopen. As a control the effect of cream or ointment without urea, was also examined.

Excised skin (for the region around a skin tumour) was used for an in vivo experiment at 30°C with the same conditions as in vitro.

The region used was to the right and left of the umbilical line and an area of 25 cm² was used for the applications.

The structure of the horny layer in the same area was examined prior to any applications. Basodexan cream and ointment with and without 10% urea were made available by the courtesy of Röhm Pharma. The experiment was performed on healthy probands, who gave their consent to the procedures.

The punch slices were cut with an ultratom DMU 3 (Reichardt) and examined by an electron microscope Dm 9 of Carl Zeiss. After fixation (2% glutaraldehyde, 2% O₅SO₄ in phosphate buffer 7.4) the slices were embedded in araldite.

Parameters of the effect of urea are: the amount of electron dense material in the horny cells, including the cell envelopes, and of the intercellular substance, the thickness of the cells and the width of the intercellular space.

Results

The composition of the horny layer structures of the skin treated with urea shows the following changes in comparison with the control skin:

The thickness of the horny cells has diminished, especially in the region towards the epidermis.

The number of horny layers, usually 11 to 12, is reduced to 8 to 10.

Additionally vacuolisation, development of cavities and changes to the inner structures towards the skin surface are obvious.

The density - the osmiophilic behaviour - changes and this is especially obvious in the horny layer, as is the smaller diameter of the transverse cross sections.

The intercellular substance and the intercellular

space show no changes. The width of the intercellular space seems in general not to be changed. The desmosomes, separated from the tonofibrils are now part of the intercellular material and disappear into the upper region of the horny layer (Fig. 1,2)




FIGURE 1

Urea ointment effect in vivo on human horny layers (x 23750)

K = Biopsy before treatment

O24 = 24 h after application of ointment without urea

OH24 = 24 h after application of 10% urea ointment

O48 = 48 h after application of ointment without urea

OH48 = 48 h after application of 10% urea ointment




FIGURE 2

Urea ointment in vitro on human horny layer (x23750)

O24 = 24 h after application of ointment without urea


OH24 = 24 h after application of 10% urea ointment

O48 = 48 h after application of ointment without urea

OH48 = 48 h after application of 10% urea ointment

The swelling of the horny cells can be combined with bulging and narrowing of the intercellular space. It is obvious that the target of the urea is the horny cell, which show evidence of loosening of the hydrogen bonds of the keratin.

This phenomenon is obviously more expressed after 48 hours (occlusive dressings for 24 hours, followed by 24 hours open application). The envelopes remain intact, irrespective of cream, ointment or time. (Fig. 3)



Urea cream effect in vivo on human horny layer (x 23750)

C48 = 48 h after application without urea

CH48 = 48 h after application of 10% urea cream

Discussion

Urea applied in vivo and in vitro shows binding to filaments of the keratin and the envelopes around the keratin filaments which are less tightly packed, and permits accumulation of water in its variable forms. The inner structure of the horny cells has changed and shows clear "splitting" of the horny filaments. These effects of urea, replacing water on the one hand and binding water on the other, and the action as a solvent on the different micro elements of the cell provide the key to a broad spectrum of effects both medical and cosmetic importance (11, 12).

From the toxicological and histological points of view there are no objections in regard to an impaired barrier function using 10% urea which permeates the skin (Fig. 4). The intercellular spaces with their lipid layers and proteoglycans are adequate to inhibit uncontrolled permeation. Steroids show an increased rate using urea. On the other hand smaller molecules such as Imidazoles (Antimycotics) show an increased accumulation in the horny layer and a smaller flux towards the corium (10).

The effects of urea do not greatly differ between




FIGURE 4

Permeating of urea 10% cream

Examinations with chamber technique in vitro using human skin (abdomen)

Application of 5 mg cream/2 cm² = 250 μ urea/cm²

TA = stripped skin (8 x with Tesafilm)

living skin and excised skin in vitro. The water uptake from the subcorneal layers to the horny layer has also to be taken into consideration. The microbial material of the horny layer is also by urea.

The base in which urea is incorporated is responsible for the depth of its action which depends on the diffusion. Urea cannot be regarded as a general enhancer of permeability of the human stratum corneum in the same sense as dimethylsulfoxide (DMSO) or laurocapram (Azone). The intercellular space with its bilipid layers is only passively involved by swelling of the horny cells without any visible change of the envelope.

References

1. Böhm W, Braun W, Pankow B, Wohlrab W, Peker J (1974): Über die Reaktion der Epidermis nach Harnstoffeinwirkung. I. Epidermales Testsystem. *Dermatol Wochenschr* **160**: 373.
2. Böhm W, Braun W, Pankow B, Wohlrab W, Peker J (1974): Epidermisreaktion nach Harnstoffeinwirkung. *Vortr Ref Dermatol Wochenschr* **160**: 597.
3. Collett JH, Flood BL (1976): Some effects of urea on drug dissolution. *J Pharm Pharmacol* **28**:206
4. Elias PM, Feingold K R, Menon G K, Grayson S, Williams M I, Grubauer G (San Francisco, Calif.) (1987): The Stratum corneum Two-Compartment Model and Its Functional Implications In: B Shroot, H. Schaefer (Ed.) *Skin Pharmacokinetics*, Karger, Basel, München, London, New York, Paris, New Delhi, Singapore, Tokyo, Sydney.
5. Hellgren L., Larsson K (1974): On the effect of urea on human epidermis. *Dermatologica* **149**:289
6. Kligman AM (1957): Dermatologic uses of urea. *Acta Derm Venereol (Stockh)* **37**:155
7. Orfanus CE (1981): Aufbau der Hornschicht im Hinblick auf ihre Funktion. In: Klaschka F (Hrsg) *Stratum corneum*. Grosse, Berlin.
8. Schwartz G (1974): Zum Einfluß von Harnstoff auf Proteine der Haut. *Vortr. Ref. Dermatol Wochenschr (Lpz)* **160**:598
9. Schwartz E (1974): Freie Aminosäuren und Harnstoff in psoriatischen und normalen, epidermalen Verhornungs. produkten. *Arch Klin Exp Dermatol* **225**:299
10. Stüttgen G (1989): Penetrationsförderung lokal applizierter Wirkstoffe durch Harnstoff. In: Raab W (Hrsg) *Harnstoff in der Dermatologie. Der Hautarzt* **40**, suppl 9.
11. Wohlrab, W. (1984): The influence of urea on the penetration kinetics of topically applied corticosteroids. *Acta Derm Venereol. (Stockh.)* **64**:233-238.
12. Wohlrab, W. (1988): Der Einfluß von Harnstoff auf die Wasser-bindungskapazität der menschlichen Hornschicht. *Dermatol. Monatsschr.* **174**:622-676.

Series Editor: P. Morganti

2

Every day Problems in Dermatology:
The Cosmetic Connection

2nd International Meeting on
Cosmetic Dermatology,
Rome, Italy: May 19-22, 1987



Edited By: P. Morganti, F.J.G. Ebling

Cosmetic Dermatology

Series Editor: P. Morganti

Volume 2

Every day Problems in Dermatology: The Cosmetic Connection

Editors: P. Morganti, F.J.G. Ebling

Every day Problems in Dermatology:

The Cosmetic Connection is the second addition to the Cosmetic Dermatology Series

This book is comprised of 41 previously unpublished papers dealing with research in various fields of cosmetic dermatology. The main themes covered are: inter-relationship between drugs and cosmetic in the skin; the efficacy of, and the reaction to, cosmetics; cosmetics in sports and work; cosmetics in relation to sexuality and pregnancy; and finally, the interconnection existing between cosmetics and diet. By so comprehensively covering the science of cosmetics, this text is indispensable to those involved in research and development for the cosmetics, toiletries and pharmaceutical industries. It will also be a great benefit to university and hospital pharmacists and health care professionals entrusted with any aspect of skin care.

CONTENTS (Main Chapters)

- Psychological aspects of every day cosmetic dermatology (E. Panconesi)
- Cosmetic, drugs and common skin disorder (W. Raab)
- Percutaneous absorption and lipids of the elderly skin (J. Wepierre)
- Mechanism of solar erythema (E. Quencez, P. Agache)
- The skin plasticisation effect of a medium chain alpha-hydroxy acid and the use of potentiators (J.C. Hill, R.J. White, M.D. Barrat, E. Mignini)
- Analytical problems of cosmetic evaluation resulting from EEC Italian regulatory procedures (L. Gagliardi, A. Amato)
- Kathon C.G.: risk of sensitization (A.C. De Groot)
- Methods for evaluating irritant - erythematogenic activity in cosmetics (A. Sertoli, S. Giorgini, C. Martinelli, M.C. Melli)
- Social problems related to perspiration: the cosmetic connection (C. Jacobson)
- Barriers creams (L.C. Parish)
- Evaluation of a new skin barrier providing water and solvent protection (P. Morganti, S.D. Randazzo)
- Cosmetology and sexuality in the history of gynaecology (G. Forleo, M. Fraticelli)
- Metabolism of steroids in human skin (A. Lanzone, A.M. Fulghesu, F.P. Bellante, A. Caruso, S. Mancuso)
- The structure and permeability of the oral mucosa (A. Jarret)
- Oral mucosa and dental care problems (E. Benagian)
- Vitamins and mineral nutrition in the skin (B. Berra, S. Zoppi, S. Rapelli)
- Good manufacturing and quality control practices in the cosmetic industry (F. Pocchiari)
- Cosmetology and public health (L. Toti)

400 pages about - Hard-bound

Price: U.S. \$ 90.00 / in Italy L. 120.000

Announcement

IV INTERNATIONAL MEETING ON COSMETIC DERMATOLOGY

PROGRESS IN COSMETIC DERMATOLOGY: SCIENCE AND SAFETY

October 30 - November 2, 1991
Villa MIANI - ROME - ITALY

PRELIMINARY PROGRAM PROGRAMMA PRELIMINARE

OCTOBER 31th THURSDAY / GIOVEDÌ 31 OTTOBRE

- 09.00 - *General considerations* / Considerazioni generali (C. Jacobson - U.S.A.)
09.30 - *Opening remarks* / Note introduttive (P. Morganti - I)
09.45 - *Cosmetic preparation: state of the art* / I prodotti cosmetici: stato dell'arte
10.00 - *Safety evaluation of cosmetic ingredients in the European Community and in other countries* / Valutazione della sicurezza degli ingredienti cosmetici nella CEE e negli altri paesi (N. Loprieno - I)
10.15 - *Role of lipids in biological membranes* / Ruolo dei lipidi nelle membrane biologiche (B. Berra - I)
10.30 - *Advances in percutaneous absorption* / L'assorbimento percutaneo secondo le più recenti acquisizioni (W. Shalla - D)
10.45 - *Liposomes: future prospects and alternative solutions* / I liposomi: prospettive future e soluzioni alternative (G. Gregoriades - U.K.)
11.00 - *Break*
11.15 - *Pediatric cosmetology: current and future trends* / La cosmesi della prima età: oggi e domani (C. Jacobson - U.S.A.)
11.30 - *Social role of cosmetics in elderly people* / Ruolo sociale dei cosmetici nella terza età (A. Tosti - I)
11.45 - *Cosmetic dermatology and mucous membranes* / Cosmesi dermatologica e mucose (S. Mancuso - I)
12.00 - *EEC cosmetic ingredients and labeling* / L'etichettatura degli ingredienti cosmetici (De Giuli - I)
12.15 - *Quality control to protect EEC consumer* / Il controllo qualità a difesa del consumatore (L. Gagliardi - I)
13.00 - *Brunch*

SKIN SURFACE AND PERMEATION / CUTE E ASSORBIMENTO

- 14.00 - *Liposomes as natural-like membranes* / I liposomi quali membrane naturali simili
14.15 - *Liposomes as topic carriers: progress working* / I liposomi come carrier per uso topico: prospettive e realtà (G. Gregoriades - U.K.)
14.30 - *Function and stability of liposomes as cosmetic vehicles* / Funzione e stabilità dei liposomi come veicoli cosmetici (E. Menegatti - I)
14.45 - *New biodegradable and biocompatible capsules for the cosmetic industry: the collaspheres* / Le nuove capsule biodegradabili e biocompatibili per l'industria cosmetica: le collasphere (A.Huc - F)
15.00 - *Discussion* / Discussione
15.30 - *The choice of vehicles in cosmetic dermatology* / L'importanza dei veicoli nella dermatologia cosmetologica (B. James - U.S.A.)
15.45 - *Activity of vehicles and diffusion through the horny layer* / Attività dei veicoli e loro diffusione attraverso lo strato corneo (W. Shalla - D)
16.00 - *Skin permeability in infants and young children* / Permeabilità cutanea nella prima infanzia e nella pubertà (C. Jacobson - U.S.A.)
16.15 - *Skin permeability in elderly people* / La permeabilità cutanea nell'anziano (F. Kerdel Vegas - YV)
16.30 - *Permeability of buccal mucosa membranes* / La permeabilità della mucosa orale (A. Jarret - U.K.)
16.45 - *Permeability of vaginal mucosa surfaces* / Permeabilità ed assorbimento della membrana vaginale (S. Mancuso - I)
17.00 - *Discussion* / Discussione
17.15 - *Break*

IV INTERNATIONAL MEETING ON COSMETIC DERMATOLOGY
PROGRESS IN COSMETIC DERMATOLOGY: SCIENCE AND SAFETY

October 30 - November 2, 1991 - Villa MIANI - ROME - ITALY

MODULO DI PRENOTAZIONE ALBERGHIERA

Il presente modulo, con il deposito richiesto, dovrà essere inviato al più presto a:
GIBI Studio Congressi - Via Marco Besso, 40 - 00191 ROMA - Tel. (06) 3273291 - 3286478 - Fax 3276288

(prego compilare a macchina o in stampatello)

Cognome Nome

Indirizzo

c.a.p. Città Tel.

Condizioni:

- I prezzi si intendono per camera, per notte e includono la prima colazione o la mezza pensione
- Tutte le camere hanno servizi privati
- La richiesta di prenotazione dovrà pervenire il più presto possibile e dovrà essere accompagnata da un deposito pari al costo della prima notte più Lit. 15.000 a camera per spese di prenotazione
- Per eventuali cancellazioni che perverranno entro il 27 giugno '91 saranno addebitate le sole spese di prenotazione, dopo tale data sarà addebitata anche la prima notte

	Camera e piccola colazione	Mezza pensione
☐ Hotel Hilton (1ª cat. lusso)		
☐ camera singola	☐ 260.000	☐ 329.000
☐ camera doppia	☐ 342.000	☐ 480.000
☐ camera doppia uso singola	☐ 301.000	☐ 370.000
☐ Hotel Clodio (2ª cat.)		
☐ camera doppia	☐ 220.000	☐ 290.000
☐ camera doppia uso singola	☐ 179.000	☐ 214.000
☐ Hotel Olympic (2ª cat.)		
☐ camera singola	☐ 170.000	
☐ camera doppia	☐ 210.000	

Vi richiedo di prenotare n. camera(e) su specificata(e) con arrivo il giorno
e partenza il giorno Allego il deposito della prima notte più Lit. 15.000 a camera a mezzo assegno
n. della banca per un importo di Lit.

N.B. - Le camere singole sono in numero limitato e potranno essere assegnate solo alle prime prenotazioni.

Note

Data Firma

IV INTERNATIONAL MEETING ON COSMETIC DERMATOLOGY
PROGRESS IN COSMETIC DERMATOLOGY: SCIENCE AND SAFETY

October 30 - November 2 , 1991 - Villa MIANI - ROME - ITALY

HOTEL RESERVATION FORM

Please type or print using block letters and return to:

GIBI Studio Congressi - Via Marco Besso, 40 - 00191 ROMA - Tel. (06) 3273291 - 3286478 - Fax 3276288

Surname Name

Address Country

Zip code City Tel.No

Conditions:

- Prices are per room, per night and include bed and breakfast or half board service
- This reservation form should reach GIBI Studio Congressi as soon as possible
- First night deposit plus Lit. 15.000 as agency fee are required at the moment of reservation
- The deposit will be deducted from the hotel bill upon departure
- Request for cancellations must be received before July 27, 1991. For cancellations received before July 27 only the agency fee will be charged. After this date also the first night deposit will be charged

	Bed and breakfast	Half board
☐ Hotel Hilton (1 ^a cat. Luxory)		
☐ single room	☐ 260.000	☐ 329.000
☐ double room	☐ 342.000	☐ 480.000
☐ double room for single use	☐ 301.000	☐ 370.000
☐ Hotel Clodio (2 ^a cat.)		
☐ double room	☐ 220.000	☐ 290.000
☐ double room for single use	☐ 179.000	☐ 214.000
☐ Hotel Olympic (2 ^a cat.)		
☐ single room	☐ 170.000	
☐ double room	☐ 210.000	

Please reserve n. room(s) arrival date departure date

I enclose first night deposit plus Lit. 15.000 per room with check n. Bank.

of Lit.

N.B. - As single rooms are very few they will be assigned on first come, first served basis.

Note

Date Signature

IV INTERNATIONAL MEETING ON COSMETIC DERMATOLOGY
PROGRESS IN COSMETIC DERMATOLOGY: SCIENCE AND SAFETY

October 30 - November 2 , 1991 - Villa MIANI - ROME - ITALY

SCHEDA DI ISCRIZIONE

Cognome Nome

Indirizzo
(dell'intestatario della fattura)

c.a.p. Città

Telefono C.F. - P. IVA
(dell'intestatario della fattura)

Quota di iscrizione: entro il 15 luglio Lit. 650.000 dopo il 15 luglio Lit. 850.000

La scheda con allegato assegno o vaglia postale intestato a GIBI Studio Congressi, dovranno essere inviati alla Segreteria Organizzativa: GIBI Studio Congressi - Via Marco Besso, 40 - 00191 ROMA - Tel. (06) 3273291 - 3286478 - Fax 3276288

Allegato assegno/vaglia n. della Banca

di Lit.

Data Firma

IV INTERNATIONAL MEETING ON COSMETIC DERMATOLOGY
PROGRESS IN COSMETIC DERMATOLOGY: SCIENCE AND SAFETY

October 30 - November 2 , 1991 - Villa MIANI - ROME - ITALY

REGISTRATION FORM

Surname Name

Address

Zip Code City

Country

Telephone No

Registration fee: before July 15 Lit. 650.000 after July 15 Lit. 850.000

This form, duly filled in and signed, with check at the order of GIBI Studio Congressi, must be sent to the Organizing Secretariat: GIBI Studio Congressi - Via Marco Besso, 40 - 00191 ROMA - Tel. (06) 3273291 - 3286478 - Fax 3276288

I enclose check n. Bank

of Italian Lire

Date Signature

PROGRESS IN COSMETIC DERMATOLOGY: SCIENCE AND SAFETY

Riassunto (solo in lingua Inglese) Abstract Reproduction Form (English language only)

Trascrivere il riassunto nel rettangolo / *Type abstract within the rectangle.*

Per ulteriori informazioni leggere le indicazioni sul retro / *For further information see directions on next page*

Titolo
Title —

Autore
Author —

Riassunto
Abstract —

Indicazioni / *Directions*

- Titolo del lavoro - con lettere maiuscole.
Title of paper - in capital letters.
- Nome degli autori - in maiuscolo e minuscolo, con il nome del relatore sottolineato.
Name of author(s) - in upper and lower case, with name of presenter underlined.
- Nome del dipartimento / ospedale / organizzazione / città - in maiuscolo e minuscolo.
Name of department / hospital / organisation / town / country - in upper and lower case.
- Interlinea 2.
Leave one line space.
- Utilizza una macchina da scrivere elettronica.
Use an electric typewriter with plastic black ribbon only.
- Il testo apparirà sul libro degli abstract come verrà inviato e gli eventuali errori rimarranno visibili.
Your text will appear in the book of abstract exactly as you send it and every error or imperfection will be visible.
- **Ultima data di ricevimento per il riassunto: 15 Luglio 1991**
Deadline for receipt of abstract: July 15,1991
- **Rispedire il riassunto a: / Please return the abstract to:**
P. Morganti, Via innocenzo XI, 41 - 00165 Roma (Italy)

NAME OF PRESENTER / NOME DEL RELATORE

Nome / Name _____

Ospedale / Hospital - Organizzazione / Organisation _____

Indirizzo / Address _____

Città / Town _____ Nazione / Country _____

Telefono / Telephone _____ Telex _____ Telefax _____

18TH WORLD CONGRESS OF DERMATOLOGY

Scholarships Available for the 18th World Congress of Dermatology

The 18th World Congress of Dermatology will take place in New York City from June 12-18, 1992. In an effort to encourage the participation of young dermatologists, the Congress will award a limited number of scholarships, as follows:

Dermatologists from Developing Countries: Applicants must be no older than 38 years of age at the time of the Congress. The scholarship will provide complimentary registration and hotel accommodations (two awardees to a room), and a moderate subsistence allowance. Awards are competitive and are contingent on sponsorship by one's national society. Abstract submission is mandatory. Obtain further information and application forms from your national society before June 1, 1991.

Dermatologists from Developed Countries: Applicant must be a Resident or Fellow in a full-time training program. The Scholarship will provide complimentary registration and a small subsistence allowance. A letter from the educational or training institution validating the applicant's status must be submitted with the application form. Abstract submission is mandatory.

Forms are available from the 18th World Congress Secretariat,
875 Kings Highway, W. Deptford, NJ 08096, USA.

Call for Abstracts for the 18th World Congress of Dermatology

The 18th World Congress of Dermatology Organizing Committee and the International League of Dermatological Societies invite the submission of abstracts for short communications to be presented at the 18th World Congress, June 12-18, 1992, New York City. Selected abstracts will be presented in the following sessions:

- **Case Presentations** - Four-minute presentations of clinical cases of exceptional scientific and/or educational interest.

- **Contributions to Clinical and Experimental Dermatology**

Oral presentations of original contributions of clinical, therapeutic or laboratory investigations.

Poster presentations of original contributions to clinical and laboratory investigation which can be effectively displayed by illustrative material (graphs, charts and tables). Authors are to be present during specified times for discussion of the posted material.

Abstracts must be submitted on the official Congress Abstract Reproduction Form and received before August 1, 1991.

Forms and submission guidelines are available from the 18th World Congress Secretariat,
875 Kings Highway, W. Deptford, NJ 08096, USA.

Chiuso in Tipografia: 15 Luglio 1991

Journal of Applied Cosmetology published quarterly by INTERNATIONAL EDIEMME, Via Innocenzo XI, 41, 00165 Roma Italy. Direttore responsabile P. Morganti. Direzione, Redazione ed Amministrazione Via Innocenzo XI, 00165 Roma Italy. Coordinamento all'edizione P. Arcuri. Stampa Edigrafica Aldina s.r.l., Via della Massimilla 50, Roma, tel. 6692801-6693099. Progetto grafico ed impaginazione STYLOgrafica Roma. Spedizione in abbonamento postale gruppo IV/70. Aut. del Trib. di Roma n. 3173/83 dell'8-7-83.

MAVIGEN IDRO SCHIUMA

L'idratante che deterge

MAVIGEN
IDRO
SCHIUMA

MAVIGEN
IDRO
SCHIUMA

DETERGENTE
IDRATANTE
agli aminoacidi

75 ml e

sperimentato clinicamente

DETERGENTE
IDRATANTE
agli aminoacidi

75 ml e

sperimentato clinicamente

NI
mavi

NI
mavi

MAVIGEN IDRO SCHIUMA

trova la sua specifica prescrizione soprattutto per le pelli grasse ed acneiche che dopo i trattamenti farmacologici con benzoin perossido, acido retinoico, antibiotici o acido azelaico hanno bisogno, in genere, di essere reidratate.



NI
mavi

La ricerca scientifica nella dermocosmesi

Mavi Sud S.r.l. - Viale dell'Industria, 1 - 04011 Aprilia (LT)

MAVI E IL SOLE



La giusta soluzione



La ricerca scientifica nella dermocosmesi

Mavi Sud S.r.l. - Viale dell'Industria, 1 - 04011 Aprilia (LT)